A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria

Annals of Surgery

Volumn 252, Issue 6, 2010, Pages 903-912

  Huang, Jiwei ^a   Yan, Lvnan ^a   Cheng, Zheyu ^a   Wu, Hong ^a   Du, Liang ^a   Wang, Jinzhou ^a   Xu, Yinglong ^a   Zeng, Yong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

cancer; liver; recurrence; survival; treatment

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; ASCITES; BILE LEAKAGE; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ELECTRODE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B; HEPATITIS C; HUMAN; ITALY; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STOMACH PERFORATION; TREATMENT OUTCOME; ULTRASOUND;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78650130194     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181efc656     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74-108.
2. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK 1979-94. Lancet. 1997;350:1142-1143. (Pubitemid 27454010)
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750. (Pubitemid 29114292)
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48:s20-s37.
5. Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171-179. (Pubitemid 38173243)
6. Duffy JP, Haitt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J. 2008;14:100-110.
7. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 4112 cases for hepatocellular carcinoma at western center. Ann Surg. 1999;229:790-799.
8. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma treatment success as defined by histologicexamination of the explanted liver. Radiology. 2005;234:954-960. (Pubitemid 40250843)
9. Choti MA. Surgical management of hepatocellular carcinoma: resection and ablation. J Vasc Interv Radiol. 2002;13:s197-s203.
10. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology. 1999;210:655-661. (Pubitemid 29124024)
11. Bonny C, Abergel A, Gayard P, et al. Radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis. Gastroenterol Clin Biol. 2002;26:735-741.
12. Jiang HC, Liu LX, Piao DX, et al. Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol. 2002;8:624-630.
13. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381-391.
14. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
15. Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome Seeding Risk for Percutaneous Approach of HCC. Cancer Treat Rev. 2007;33:437-447. (Pubitemid 47324228)
16. Dhya AL, Derek AO, Graeme JP. Biopsy of solid liver tumors: adverse consequences. Hepatobiliary Pancreat Dis Int. 2008;7:325-327.
17. Takuma T, Haruhiko Y, Shuichiro S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43:1101-1108.
18. Shi M, Zhang CQ, Zhang YQ, et al. Micrometastasis of solitary hepatocel-lular carcinoma and appropriate resection margin. World J Surg. 2004;28: 376-381. (Pubitemid 38525871)
19. Regimbeu JM, Kianmanesh R, Farges O, et al. Extent of liver resection influences the outcome in patient with cirrhosis and small hepatocellular carcinoma. Surgery. 2002;131:311-317. (Pubitemid 34229784)
20. Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242: 252-259. (Pubitemid 41033442)
21. Sasaki A, Kai S, Iwashita Y, et al. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer. 2005;103:299-306. (Pubitemid 40129289)
22. Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepa-tocellular carcinoma: evidence for spread via the portal vein as efferent vessel. Am J Gastroenterol. 1996;91(8):1610-1615. (Pubitemid 26269180)
23. Ming SR, Guo P, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma. Ann Surg. 2007;245:36-43.
24. Hoffman AL, Wu SS, Obaid AK, et al. Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors. Am Surg. 2002;68:1038-1043. (Pubitemid 44943156)
25. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 1996;7:1792-1796. (Pubitemid 26125178)
26. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hep-atology. 2001;33:1124-1129. (Pubitemid 32378211)
27. Guglielmi A, Ruzzenente A, Battocchia A, et al. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology. 2003;50:480-484. (Pubitemid 36390549)
28. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352-1360. (Pubitemid 39657009)
29. Marin-Harg Reaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol. 2003;47:13-27. (Pubitemid 36802322)
30. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201-1209. (Pubitemid 40328091)
31. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961-967. (Pubitemid 40250844)
32. Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofre-quency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616-628. (Pubitemid 41126091)
33. Cabassa P, Donato F, Simeone F, et al. Radiofrequency ablation of hepatocellu-lar carcinoma: long-term experience with expandable needle electrodes. AJR Am J Roentgenol. 2006;186:s316-s321. (Pubitemid 46114737)
34. Ng KK, Poon RT, Lo CM, et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointestinal Surg. 2008;12:183-191.
35. Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453-459.